Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark D Williams

Showing results (81-90 of 114) with videos related to

Pageof 12
Sort By:
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|April 1, 2006
ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsisBrahm Goldstein, Simon Nadel, Mark Peters, et al.
Critical Care (London, England)|September 13, 2008
Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsisPierre-François Laterre, William L Macias, Jonathan Janes, et al.
Critical Care Medicine|October 24, 2009
Diabetes does not alter mortality or hemostatic and inflammatory responses in patients with severe sepsisMichiel E Stegenga, Jean-Louis Vincent, George M Vail, et al.
Surgical Infections|February 3, 2005
Safety of drotrecogin alfa (activated) in surgical patients with severe sepsisDonald E Fry, Gregory Beilman, Steven Johnson, et al.
Mayo Clinic Proceedings|October 6, 2022
Shaping the Screening, Behavioral Intervention, and Referral to Treatment (SBIRT) Model for Treatment of Alcohol Use Disorder in the COVID-19 EraCelia C Kamath, Sydney S Kelpin, Christi A Patten, et al.
BMJ Open Quality|January 16, 2018
A quality improvement project aimed at adapting primary care to ensure the delivery of evidence-based psychotherapy for adult anxietyMark D Williams, Craig N Sawchuk, Nathan D Shippee, et al.
Journal of Critical Care|June 6, 2007
International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safetyPierre-Francois Laterre, David R Nelson, William Macias, et al.
Surgical Infections|February 3, 2005
Static and dynamic assessment of biomarkers in surgical patients with severe sepsisStephen F Lowry, Samir Awad, Henri Ford, et al.
JMIR Research Protocols|March 26, 2025
Treatment of Substance Use Disorders With a Mobile Phone App Within Rural Collaborative Care Management (Senyo Health): Protocol for a Mixed Methods Randomized Controlled TrialTyler S Oesterle, Nicholas L Bormann, Margaret M Paul, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|January 14, 2005
Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administrationHenry J Mann, Sarah L Demmon, Debra A Boelk, et al.
Pageof 12

Showing results (81-90 of 114) with videos related to

Sort By:
Pageof 12
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|April 1, 2006
ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsisBrahm Goldstein, Simon Nadel, Mark Peters, et al.
Critical Care (London, England)|September 13, 2008
Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsisPierre-François Laterre, William L Macias, Jonathan Janes, et al.
Critical Care Medicine|October 24, 2009
Diabetes does not alter mortality or hemostatic and inflammatory responses in patients with severe sepsisMichiel E Stegenga, Jean-Louis Vincent, George M Vail, et al.
Surgical Infections|February 3, 2005
Safety of drotrecogin alfa (activated) in surgical patients with severe sepsisDonald E Fry, Gregory Beilman, Steven Johnson, et al.
Mayo Clinic Proceedings|October 6, 2022
Shaping the Screening, Behavioral Intervention, and Referral to Treatment (SBIRT) Model for Treatment of Alcohol Use Disorder in the COVID-19 EraCelia C Kamath, Sydney S Kelpin, Christi A Patten, et al.
BMJ Open Quality|January 16, 2018
A quality improvement project aimed at adapting primary care to ensure the delivery of evidence-based psychotherapy for adult anxietyMark D Williams, Craig N Sawchuk, Nathan D Shippee, et al.
Journal of Critical Care|June 6, 2007
International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safetyPierre-Francois Laterre, David R Nelson, William Macias, et al.
Surgical Infections|February 3, 2005
Static and dynamic assessment of biomarkers in surgical patients with severe sepsisStephen F Lowry, Samir Awad, Henri Ford, et al.
JMIR Research Protocols|March 26, 2025
Treatment of Substance Use Disorders With a Mobile Phone App Within Rural Collaborative Care Management (Senyo Health): Protocol for a Mixed Methods Randomized Controlled TrialTyler S Oesterle, Nicholas L Bormann, Margaret M Paul, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|January 14, 2005
Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administrationHenry J Mann, Sarah L Demmon, Debra A Boelk, et al.
Pageof 12